Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 621

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 621
---
 revenue due to completion of research and development services provided by Kineta related to the Merck Neuromuscular License Agreement with Merck to support research, development and commercialization of products for treatment of neuromuscular diseases, partially offset by a $338,000 decrease in prepaid expenses. The noncash charges primarily consisted of $3.9 million in stock-based compensation and $739,000 noncash operating lease expense, partially offset by a $1.6 million gain on change in fair value of rights from the Private Placement. Investing Activities Cash provided by investing activities was zero for the year ended December 31, 2024 and $331,000 for the year ended December 31, 2023 consisting of cash received from the sale of certain property and equipment. Financing Activities Cash provided by financing activities was $6.3 million for the year ended December 31, 2024, primarily related to advances received from TuHURA of $5.9 million and proceeds of $500,000 from the issuance of Kineta’s common stock, partially offset by repayment of a note payable of $150,000. Cash provided by financing activities for the year ended December 31, 2023 was $8.5 million, primarily related to $8.0 million in net proceeds from the Private Placement and $600,000 in proceeds from the issuance of Kineta’s common stock, partially offset by $123,000 in repayments of finance lease obligations. 401

Debt Obligations

Notes Payable

As of December 31, 2024, Kineta had outstanding notes payable in an aggregate principal amount of $629,000 at an interest rate of 6%. Notes payable of $379,000 matured on June 30, 2024 and a note payable of $250,000 matured on July 31, 2024. As of December 31, 2024, the notes remain unpaid and are payable upon demand by the holders.

See Note 5 to Kineta’s consolidated financial statements included in this joint proxy statement/prospectus for additional information regarding Kineta notes payable.

Other Contractual Obligations and Commitments

Kineta’s cash requirements greater than 12 months are related to other contractual obligations and commitments related to license agreements.

Kineta has entered into a number of strategic license agreements pursuant to which Kineta has acquired rights to specific assets, technology and intellectual property. In accordance with these agreements, Kineta is obligated to pay, among other items,